Economics blog

Unit 3 Micro: Glaxo SmithKline fined $3 billion for off-label marketing

The scale of the fine is staggering, Glaxo SmithKline has been found guilty of off-label marketing - an illegal strategy - GSK targeted the antidepressant Paxil at patients under age 18 when it was approved only for adults, and promoted the drug Wellbutrin for uses it was not approved for, including weight loss and treatment of sexual dysfunction

This is corporate irresponsibility on a grand scale as this new report makes clear.

Guardian: GlaxoSmithKline fined $3bn for healthcare fraud

Daily Mail: GlaxoSmithKline to pay $3billion fine after pleading guilty to healthcare fraud - the biggest in U.S. history

News video:

See also

 

Featured
Exam coaching workshops

AS Micro/Macro Economics Exam Coaching Workshop (combined)

This intensive one-day exam coaching & revision workshop will help improve your AS Economics students ability to maximise their performance in the 2015 exam

Learn more ›